Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases
Authors:
- Mithat GönenMGMithat Gönen
- Hiromichi ItoHIHiromichi Ito
- Ronald P. DeMatteoRDRonald P. DeMatteo
- Peter J. AllenPAPeter J. Allen
- Yuman FongYFYuman Fong
- Leslie H. BlumgartLBLeslie H. Blumgart
- William R. JarnaginWJWilliam R. Jarnagin
- Michael I. D'AngelicaMDMichael I. D'Angelica
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS TrialJournal of Clinical Oncology, 2008
- ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimenBritish Journal of Cancer, 2008
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Cetuximab for the Treatment of Colorectal CancerNew England Journal of Medicine, 2007
- Current status of excision repair cross complementing-group 1 (ERCC1) in cancerCancer Treatment Reviews, 2007
- Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver MetastasesAnnals of Surgery, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- Maximally Selected Chi Square Statistics1982